{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-234722","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2025-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.393670+00:00","generated_at":"2026-05-17T04:13:14.393399+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aardvark gets FDA alignment to lower Phase 3 PWS trial min age to 10","bullets":["FDA aligned on protocol amendment for Phase 3 HERO trial of ARD-101, lowering minimum age from 13 to 10 years old.","Expansion broadens patient population in Prader-Willi Syndrome; topline data readout expected in Q3 2026.","CEO cites community support and historical data suggesting younger patients benefit from early intervention."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-234722","json":"https://secwatch.observer/filing/0001193125-25-234722.json","markdown":"https://secwatch.observer/filing/0001193125-25-234722.md","text":"https://secwatch.observer/filing/0001193125-25-234722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312525234722/0001193125-25-234722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312525234722/ck0001774857-20251008.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:13:14.393399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}